TNF and neoplasm: Once interacting with the TLR7 on the cancer cell surface, this synthetic TLR activator can lead to the release of cytokines and chemokines such as tumor necrosis factor-alpha (TNF-α), interleukin-12 (IL-12), and IL-6, thus creating DC activation and specific tumor immune response [35].